Dow Jones Industrial Average Stays Hot; Nasdaq Topples 6,000

The Red-Hot ETF Headed for Record Highs

Apr 25, 2017 at 11:52 AM
facebook twitter linkedin


The Dow Jones Industrial Average (DJIA) is on fire for a second straight day, while the Nasdaq Composite (COMP) has toppled the 6,000 level for the first time ever -- hitting a record high of 6,022.65. A string of upbeat earnings reports from Dow stocks 3M Co (NYSE:MMM), Caterpillar Inc. (NYSE:CAT), DuPont (NYSE:DD), and McDonald's Corporation (NYSE:MCD) is pouring fuel on the fire, which started yesterday after France's presidential election results triggered a relief rally. Plus, on the data front, traders are digesting a bigger-than-forecast rise in U.S. housing prices and new home sales, and gearing up for details on President Trump's highly anticipated tax plan.

Continue reading for more on today's market -- and don't miss:

  • Record highs could be "eminently achievable" for this red-hot semiconductor ETF, explains our founder and CEO Bernie Schaeffer.
  • Don't expect Best Buy stock to slow down just yet.
  • Plus, pre-earnings options traders target Twitter; the stock Anthem's killing; and why these drug shares are 5% higher.

stock market today

Among the names with unusual options volume today is Twitter Inc (NYSE:TWTR), running at twice the average intraday pace. The accelerated action comes just ahead of tomorrow's TWTR earnings report. The most active option is the weekly 4/28 15-strike call, where there seems to be a mix of buy- and sell-to-open activity.

One of the worst performers on the Nasdaq is Express Scripts Holding Company (NASDAQ:ESRX), down 11.6% at $59.46. Leveling shares of the pharmacy firm -- currently short-sale restricted -- is contractual drama with customer Anthem Inc (NYSE:ANTM), as well as disappointing revenue data and negative analyst attention. In fact, ESRX stock earlier touched a four-year low of $57.80.

express scripts stock chart today

Among the top gainers on the Nasdaq is drug stock Biogen Inc (NASDAQ:BIIB), up 4.8% at $290.17. A well-received earnings report, strengthened by the launch of muscular atrophy treatment Spinraza, is bolstering the shares.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

SCHAEFFER'S JULY STOCKS REPORT AD
 


 


 
Special Offers from Schaeffer's Trading Partners